International symposium - Current status and future role of HTA in Japan and other countries
Recently, there have been increasing concerns about the impact of the increase in expensive healthcare technologies on medical insurance finances, and trial implementation of cost-effectiveness evaluations on medicines and medical devices began in fiscal 2016. From April 2019, the full-scale introduction of cost-effectiveness evaluations will finally begin in Japan. In other countries, there are already many public health technology assessment (HTA) agencies responsible for these tasks. In response to these changes, the Center for Outcomes Research and Economic Evaluation for Health (C2H) was established in Japan in April 2018 within the National Institute of Public Health. The following symposium was held for the purpose of having personnel from the HTA agencies of other preceding countries, such as NICE in the UK, explain the mechanism of health technology assessment in their respective countries and to also promote the importance of cost-effectiveness evaluations in Japan.
Date and Time: Monday, February 25, 2019 1 pm to 5:30 pm
Theme: Current Status and Future Role of HTA in Japan and Other Countries
Venue：The GRAND HALL Shinagawa (3rd Floor, Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo)